Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
15
02
2020
revised:
01
06
2020
accepted:
20
07
2020
pubmed:
30
7
2020
medline:
7
10
2021
entrez:
30
7
2020
Statut:
ppublish
Résumé
Kinases are enzymes that are important for cellular functions, but their overexpression has strong connections with carcinogenesis, rendering them important targets for anticancer drugs. Thymoquinone (TQ) is a natural compound with proven anticancer activities, at least in preclinical studies. TQ can target several kinases, including phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), Janus kinase/signal transducers and activators of transcription (JAK/STAT), polo-like kinase 1 (PLK1), and tyrosine kinase in different cancer cells and animal models. Inhibiting the activity of kinases or suppressing their expression might be among the mechanisms of TQ anticancer activity. In this review, we discuss the role of TQ in kinase regulation in different cancer models.
Identifiants
pubmed: 32721537
pii: S1359-6446(20)30299-3
doi: 10.1016/j.drudis.2020.07.019
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Benzoquinones
0
Protein Kinase Inhibitors
0
Protein Kinases
EC 2.7.-
thymoquinone
O60IE26NUF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2294-2306Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.